Who We Are

About Us

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of potentially first-in-class therapeutics.

Management Team

Diverse Expertise, Singular Vision

  Genetics and AMD
GENETICS AND AMD
Target Biology
TARGET BIOLOGY
Technology
TECHNOLOGY
SCIENTIFIC FOUNDERS
Paul Barlow, Ph.D.
The University of Edinburgh
Andrew Herbert, Ph.D.
The University of Edinburgh
SCIENTIFIC ADVISORY BOARD MEMBERS
Napoleone Ferrara, M.D.
University of California San Diego
Alan Wright, M.B., Ch.B., Ph.D.
The University of Edinburgh
John Atkinson, M.D.
Washington University in St. Louis
Michael Ehrmann, Ph.D.
University of Essen-Duisberg
Kevin Marchbank, Ph.D.
Newcastle University
Aravind Asokan, Ph.D.
University of North Carolina
Shannon Boye, Ph.D.
University of Florida
Claudio Punzo, Ph.D.
University of Massachusetts Medical School
Chris Mueller, Ph.D., Sc.M.
University of Massachusetts Medical School

SCIENTIFIC FOUNDERS

GENETICS AND AMD
TARGET BIOLOGY

SCIENTIFIC ADVISORY BOARD MEMBERS

GENETICS AND AMD
TARGET BIOLOGY
TECHNOLOGY

Board of Directors

Our Investors

We are proud to be funded by leading life science investors, including:

  • Atlas Venture
  • Lightstone
  • OrbiMed